- Home
- VMD vs RIGL Comparison
VMD vs RIGL Comparison
Compare VMD & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VMD
- RIGL
- Stock Information
- Founded
- VMD 2006
- RIGL 1996
- Country
- VMD United States
- RIGL United States
- Employees
- VMD N/A
- RIGL N/A
- Industry
- VMD
- RIGL Biotechnology: Pharmaceutical Preparations
- Sector
- VMD
- RIGL Health Care
- Exchange
- VMD Nasdaq
- RIGL Nasdaq
- Market Cap
- VMD 279.4M
- RIGL 335.5M
- IPO Year
- VMD N/A
- RIGL 2000
- Fundamental
- Price
- VMD $6.91
- RIGL $18.62
- Analyst Decision
- VMD
- RIGL Buy
- Analyst Count
- VMD 0
- RIGL 5
- Target Price
- VMD N/A
- RIGL $36.40
- AVG Volume (30 Days)
- VMD 192.5K
- RIGL 192.9K
- Earning Date
- VMD 08-06-2025
- RIGL 08-05-2025
- Dividend Yield
- VMD N/A
- RIGL N/A
- EPS Growth
- VMD 19.95
- RIGL N/A
- EPS
- VMD 0.30
- RIGL 2.08
- Revenue
- VMD $232,793,000.00
- RIGL $203,077,000.00
- Revenue This Year
- VMD $17.35
- RIGL $14.41
- Revenue Next Year
- VMD $12.87
- RIGL $15.97
- P/E Ratio
- VMD $23.30
- RIGL $9.02
- Revenue Growth
- VMD 19.97
- RIGL 70.16
- 52 Week Low
- VMD $6.14
- RIGL $7.48
- 52 Week High
- VMD $9.81
- RIGL $29.82
- Technical
- Relative Strength Index (RSI)
- VMD 55.11
- RIGL 39.75
- Support Level
- VMD $6.81
- RIGL $18.14
- Resistance Level
- VMD $7.08
- RIGL $19.21
- Average True Range (ATR)
- VMD 0.20
- RIGL 0.84
- MACD
- VMD 0.03
- RIGL -0.28
- Stochastic Oscillator
- VMD 67.92
- RIGL 10.89
About VMD Viemed Healthcare Inc.
Viemed Healthcare Inc is a provider of medical equipment and home therapy to patients with respiratory disease, oxygen problems, sleep apnea and PAP treatment. The company also provides services such as respiratory disease management, neuromuscular care, in-home sleep testing and sleep apnea treatment, oxygen therapy, respiratory equipment rentals, and healthcare staffing services. The company generates majority its revenue from medical equipment rental, sales and supply.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.